Study: Kre-Celazine® as a Viable Treatment for Juvenile Arthritis

All American Pharmaceutical to field KarboLyn Clinical Study
May 19, 2014
MBRCT Grant Awarded to All American Pharmaceutical
July 1, 2014
Show all

Study: Kre-Celazine® as a Viable Treatment for Juvenile Arthritis

Kre-Celazine® as a Viable Treatment for Juvenile Rheumatoid/Idiopathic Arthritis: A Pilot Study

Jeff Golini, Wendy Jones, MS
All American Pharmaceutical, Billings, MT and Royal Knight, Incorporated, Rochester, MN


Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/ JIA) is a physiologically complex, chronic childhood autoimmune–related inflammatory disease of unknown etiology. An initial diagnosis has been confirmed in infants less than one year, to individuals older than 17 years.

Only two of the three sub-classifications: pauciarticular (affecting four or fewer joints), and polyarticular (impacting at least five joints) have shown a clear female gender
preference. Systemic onset displays no gender preference and is the most aggressively active, fibril, and includes multi-organ, involvement.

Study Objective

Ascertain whether an oral, non-prescription nutritional supplement (proprietary alkali-buffered creatine monohydrate and cetylated fatty acids mixture) was efficacious in reducing/eliminating refractory pain and inflammation without untoward effects.

Participants and Method

Juveniles less than 17 years of age, with confirmed JRA/JIA, unresponsive to standard anti-inflammatory therapy, and who demonstrated palpable signs of inflammation, restricted range of motion, elevated inflammatory markers: CRP, ANA, and accelerated ESR.

Each participant received two 750 mg capsules (total, 1,500 mg) of Kre- Celazine®. This dose was taken daily (one in the morning, and one in the evening, on an empty stomach, and only with water) for a period of 30 consecutive days.

Each family was provided with a Pain Journal to be completed weekly, indicating perceived level of physical discomfort for each afflicted joint. At the conclusion of the 30 day treatment period, each individual returned to the hospital for re-examination and a fasting blood draw.


By the end of the study, Range of Motion was rated ‘normal’ by all physician. Two participants reported feeling, “Fully recovered” and began playing basketball at their school. (Detailed numbers can be seen by clicking the Research Poster Presentation image below)


The study demonstrated the safety and efficacy of this treatment in juveniles who had not obtained satisfactory relief from their previous prescription medication.

Kre-Celazine® is capable of significantly improving or resolving unresolved JRA/JIA symptoms without undesirable side effects.

Research Poster Presentation Image:

Dr. Jeff Golini
Dr. Jeff Golini
Dr. Jeff Golini is the Founder, CEO and Executive Scientist of All American Pharmaceutical. He holds numerous patents for innovative compounds such as, Kre-Alkalyn buffered creatine monohydrate, Karbolyn, the high-performance carbohydrate, and Kre-Celazine.

Comments are closed.